Qyuns Therapeutics Co., Ltd. has scheduled a board meeting for 19 August 2026 to consider and approve the Group’s interim results for the six-month period ended 30 June 2026, according to an announcement released on 7 August 2026. The agenda also includes authorising the publication of the interim report and addressing other corporate matters.
The Board is led by Chairman and Executive Director Mr. Qiu Jiwan, with executive directors Mr. Wu Yiliang and Mr. Lin Weidong; non-executive directors Mr. Yu Xi and Mr. Wu Zhiqiang; and independent non-executive directors Mr. Fung Che Wai, Anthony, Dr. Zou Zhongmei and Dr. Ling Jianqun.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments